Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications

References

• Liu J, Ren Z-H, Qiang H, et al. Trends in the incidence of diabetes mellitus: results from the global burden of disease study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20(1):1415. .
   PubMed Web of Science ®Google Scholar
• Magliano DJ, Islam RM, Barr ELM, et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ 2019;366:l5003–l.
   PubMedGoogle Scholar
• Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396(10267):2019–2082.
   PubMed Web of Science ®Google Scholar
• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963–970.
   PubMed Web of Science ®Google Scholar
• Afroz A, Zhang W, Wei Loh AJ, et al. Macro- and micro-vascular complications and their determinants among people with type 2 diabetes in Bangladesh. Diabetes Metab Syndr. 2019;13(5):2939–2946.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF atlas ninth edition. 2019. Available from: https://diabetesatlas.org/upload/resources/material/20200106_152211_IDFATLAS9e-final-web.pdf
   Google Scholar
• Bhuyan KC, Fardus J. Factors responsible for diabetes among adult people of Bangladesh. Am J Biomed Sci & Res. 2019;2(4):137–142.
   Google Scholar
• Biswas T, Pervin S, Tanim MIA, et al. Bangladesh policy on prevention and control of non-communicable diseases: a policy analysis. BMC Public Health. 2017;17(1):582.
   PubMedGoogle Scholar
• Biswas T, Haider MM, Das Gupta R, et al. Assessing the readiness of health facilities for diabetes and cardiovascular services in Bangladesh: a cross-sectional survey. BMJ Open. 2018;8(10):e022817.
   PubMed Web of Science ®Google Scholar
• Chowdhury MZI, Rahman M, Akter T, et al. Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis. Clin hyperten. 2020;26(1):10.
   PubMedGoogle Scholar
• Fottrell E, Ahmed N, Shaha SK, et al. Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey. BMJ Glob Health. 2018;3(6):e000787.
   Web of Science ®Google Scholar
• Islam SMS, Islam MT, Islam A, et al. National drug policy reform for noncommunicable diseases in low-resource countries: an example from Bangladesh. Bull World Health Organ. 2017;95(5):382–384.
   PubMed Web of Science ®Google Scholar
• Maffi P, Secchi A. The burden of diabetes: emerging data. Develop ophthalmol. 2017;60:1–5.
   PubMedGoogle Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2(7):553–561.
   PubMed Web of Science ®Google Scholar
• Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649–662. .
   PubMed Web of Science ®Google Scholar
• Almeida P, Silva TBC, De Assis Acurcio F, et al. Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with nph insulin: a systematic review and policy implications. Patient. 2018;11(4):377–389.
   PubMedGoogle Scholar
• Ewen M, Joosse HJ, Beran D, et al. Insulin prices, availability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019;4(3):e001410.
   PubMed Web of Science ®Google Scholar
• Shariful Islam SM, Lechner A, Ferrari U, et al. Healthcare use and expenditure for diabetes in Bangladesh. BMJ Glob Health. 2017;2(1):e000033–e.
   PubMed Web of Science ®Google Scholar
• Kasonde L, Tordrup D, Naheed A, et al. Evaluating medicine prices, availability and affordability in Bangladesh using World health organisation and health action International methodology. BMC Health Serv Res. 2019;19(1):383.
   PubMedGoogle Scholar
• Afroz A, Alam K, Ali L, et al. Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study. BMC Health Serv Res. 2019;19(1):601.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Zhang C, Swe KT, et al. Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: a Bayesian analysis. PloS One. 2020;15(1):e0227565–e.
   PubMed Web of Science ®Google Scholar
• United Nations. Progress towards the sustainable development goals. 2017. [cited 2021 Feb 24]. Available from: https://www.un.org/ga/search/view_doc.asp?symbol=E/2017/66&Lang=E
   Google Scholar
• Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903.
   PubMed Web of Science ®Google Scholar
• Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open. 2017;7(6):e016730.
   PubMed Web of Science ®Google Scholar
• Lothian Formulary. 6.1.1 Insulins. 2020. [cited 2021 Feb 6]. Available from: https://www.ljf.scot.nhs.uk/LothianJointFormularies/Adult/6.0/6.1/6.1.1/Pages/default.aspx
   Google Scholar
• Greener M. Why isn’t the NHS making the most of biosimilar insulin? Prescriber August. 2019; 21–24.
   Google Scholar
• Godman B. Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist. Bangladesh J Med Sci. 2021;20(1):5–10.
   Web of Science ®Google Scholar
• Haque M, Islam S, Iqbal S, et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh J Med Sci. 2020;19:S36–S50.
   Google Scholar
• odman B, Haque M, Islam S, et al. Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future. Front Public Health. 2020;8:744.
   Web of Science ®Google Scholar
• Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol. 2014;5:219.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Godman B, Huys I, et al. The expiry of Humira ® market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2021;11:1993.
   Web of Science ®Google Scholar
• ad M, Salem A, Oortwijn W, et al. Mapping of current obstacles for rationalizing use of medicines (CORUM) in Europe: current situation and potential solutions. Front Pharmacol. 2020;11:144.
   PubMed Web of Science ®Google Scholar
• Sefah I, Ogunleye O, Essah D, et al. Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. Front Pharmacol. 2021;11:2055.
   Web of Science ®Google Scholar
• Salary Explorer. Average salary in Bangladesh 2021. [cited 2021 Feb 4]. Available from: http://www.salaryexplorer.com/salary-survey.php?loc=18&loctype=1
   Google Scholar
• Godman B, Basu D, Pillay Y, et al. Ongoing and planned activities to improve the management of patients with type 1 diabetes across Africa; implications for the future. Hosp Pract. 2020;48(2):51–67.
   PubMedGoogle Scholar
• alungia CA, Mwale M, Sondashi IS, et al. Availability of essential antihypertensive and antidiabetic medicines in public health facilities in Lusaka District, Zambia. Med J Zambia. 2017;44(3):140–148.
   Google Scholar
• Davio K. After biosimilar deals, UK spending on adalimumab will drop by 75%. 2018. [cited 2021 Feb 6]. Available from: https://www.centerforbiosimilars.com/news/after-biosimilar-deals-uk-spending-on-adalimumab-will-drop-by–75
   Google Scholar
• Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Systemat Rev. 2020;11:Cd005613.
   PubMedGoogle Scholar